Park Avenue Securities LLC Acquires 4,739 Shares of DexCom, Inc. (NASDAQ:DXCM)

Park Avenue Securities LLC grew its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 35.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 18,086 shares of the medical device company's stock after purchasing an additional 4,739 shares during the period. Park Avenue Securities LLC's holdings in DexCom were worth $1,235,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Private Trust Co. NA raised its position in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after acquiring an additional 245 shares during the period. Optiver Holding B.V. acquired a new stake in shares of DexCom in the fourth quarter valued at about $33,000. TD Private Client Wealth LLC lifted its stake in DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares in the last quarter. Larson Financial Group LLC boosted its stake in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after buying an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC purchased a new stake in shares of DexCom in the fourth quarter valued at about $38,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on DXCM. Barclays lifted their target price on DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a research report on Monday, May 5th. Morgan Stanley boosted their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research note on Friday, February 14th. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Citigroup reaffirmed a "buy" rating and set a $102.00 price objective (up previously from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Finally, Mizuho assumed coverage on DexCom in a research report on Thursday, April 10th. They set an "outperform" rating and a $85.00 price objective for the company. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, DexCom presently has an average rating of "Moderate Buy" and an average target price of $98.32.

DexCom Stock Down 0.2%

Shares of NASDAQ DXCM traded down $0.14 during midday trading on Thursday, reaching $82.85. The company's stock had a trading volume of 2,805,300 shares, compared to its average volume of 4,336,855. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $117.91. The stock has a market capitalization of $32.49 billion, a price-to-earnings ratio of 57.94, a PEG ratio of 2.30 and a beta of 1.46. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The stock has a 50 day simple moving average of $77.65 and a 200-day simple moving average of $79.25.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. DexCom's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.32 earnings per share. Equities research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Sadie Stern sold 6,184 shares of the stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total transaction of $526,320.24. Following the completion of the sale, the executive vice president now directly owns 109,621 shares in the company, valued at $9,329,843.31. This represents a 5.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Michael Jon Brown sold 10,000 shares of the business's stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $84.28, for a total value of $842,800.00. Following the completion of the transaction, the executive vice president now directly owns 95,602 shares in the company, valued at approximately $8,057,336.56. This trade represents a 9.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 16,536 shares of company stock worth $1,393,876 in the last ninety days. 0.32% of the stock is owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.